Gene Symbol: NTRK2 (formerly TRKB)
Full Name: Neurotrophic Receptor Tyrosine Kinase 2
Chromosomal Location: 9q21.33
NCBI Gene ID: 4915
OMIM: 600456
UniProt: Q16620
Ensembl ID: ENSG00000148053
The NTRK2 gene encodes the Tropomyosin receptor kinase B (TrkB), a member of the neurotrophic tyrosine receptor kinase (NTRK) family. TrkB is the high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), playing critical roles in neuronal survival, differentiation, synaptic plasticity, and cognitive function. TrkB signaling is essential for development and maintenance of the central and peripheral nervous systems, and its dysfunction has been implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
¶ Gene Structure and Expression
The NTRK2 gene spans approximately 340 kb on chromosome 9q21.33 and consists of 24 exons. The gene encodes multiple transcript variants through alternative splicing, including:
- TrkB.FL (full-length): 796 amino acids, contains the kinase domain
- TrkB.T1 (truncated isoform): 476 amino acids, acts as a dominant-negative regulator
- TrkB.T2 (truncated isoform): Alternative splice variant
TrkB is predominantly expressed in the central nervous system (CNS), with highest levels in:
- Hippocampus (CA1-CA3 pyramidal neurons, dentate gyrus granule cells)
- Cerebral cortex (layers II-IV)
- Basal forebrain cholinergic neurons
- Substantia nigra pars compacta (dopaminergic neurons)
- Cerebellum (Purkinje cells)
- Peripheral nervous system (sensory and motor neurons)
Lower expression is detected in non-neuronal tissues including pancreatic β-cells, skeletal muscle, and immune cells.
¶ Domain Architecture
TrkB is a type I transmembrane glycoprotein with the following structural domains:
-
Extracellular Domain (residues 1-430)
- Leucine-rich repeat (LRR) domains (LRR1-3)
- Ig-like C2-type domains (Ig-C2)
- Cysteine-rich domains
- N-glycosylation sites
-
Transmembrane Domain (residues 431-455)
- Single α-helical transmembrane segment
-
Intracellular Domain (residues 456-796)
- Kinase domain (residues 516-796)
- Multiple tyrosine phosphorylation sites (Y490, Y515, Y705, Y816, Y817)
- Shc binding site (Y490)
- PLCγ binding site (Y815)
- N-glycosylation in the extracellular domain
- Palmitoylation at cysteine residues
- Phosphorylation at multiple tyrosine residues (activation sites)
- Proteolytic cleavage generating truncated isoforms
¶ Ligand Binding and Receptor Activation
TrkB binds two primary ligands with different affinities:
- Brain-Derived Neurotrophic Factor (BDNF): High-affinity binding (Kd ~10⁻¹¹ M)
- Neurotrophin-4 (NT-4): Slightly lower affinity (Kd ~10⁻¹⁰ M)
Ligand binding induces receptor dimerization and autophosphorylation at tyrosine residues within the intracellular domain, activating multiple downstream signaling cascades.
- Key molecules: PI3K p85/p110, Akt1/2/3, mTORC1, 4E-BP1, S6K
- Outcomes: Neuronal survival, protein synthesis, synaptic plasticity
- Key molecules: Ras, Raf, MEK1/2, ERK1/2, ELK-1, c-Fos
- Outcomes: Neuronal differentiation, long-term potentiation
- Key molecules: PLCγ1, PKC isoforms, CaMKII, CREB
- Outcomes: Synaptic plasticity, LTP, neurotransmitter release
During nervous system development, TrkB/BDNF signaling:
- Promotes neuronal survival (prevents apoptosis)
- Regulates axonal guidance and dendritic arborization
- Controls synaptogenesis and synapse maturation
- Mediates activity-dependent refinement of neuronal circuits
TrkB signaling is crucial for both:
- Long-term potentiation (LTP): BDNF enhances synaptic strength through NMDA receptor modulation and AMPA receptor trafficking
- Long-term depression (LTD): Regulates synaptic weakening and spine remodeling
TrkB activation provides neuroprotection through:
- Inhibition of apoptotic pathways (caspase inhibition)
- Antioxidant enzyme expression
- Anti-inflammatory effects
- Mitochondrial function maintenance
- Reduced TrkB expression: Observed in AD brain, particularly in hippocampus and cortex
- BDNF/TrkB signaling impairment: Contributes to synaptic loss and cognitive decline
- Therapeutic potential: TrkB agonists (BDNF mimetics, small molecules) in development
- Genetic variants: NTRK2 polymorphisms associated with AD risk in some populations
- Neuroprotective role: BDNF/TrkB signaling supports dopaminergic neuron survival
- Therapeutic approaches: AAV-BDNF delivery explored in preclinical models
- Combination therapy: TrkB activation with other neurotrophic factors
- BDNF transport disruption: Mutant huntingtin impairs BDNF/TrkB signaling
- Therapeutic target: Restoring TrkB signaling to promote neuronal survival
- Research: TrkB agonists show promise in HD models
- Motor neuron vulnerability: Reduced TrkB expression in motor neurons
- Therapeutic potential: Enhancing neurotrophic support
- Clinical trials: BDNF delivery trials showed limited efficacy
¶ Depression and Anxiety
- Monoamine-independent effects: TrkB signaling mediates antidepressant efficacy
- Fast-acting antidepressants: Ketamine works partly through TrkB activation
- Research: TrkB-selective compounds in development
| Agent |
Type |
Development Stage |
Notes |
| 7,8-DHF |
Small molecule |
Preclinical |
TrkB-selective agonist |
| R13 |
Peptide mimetic |
Preclinical |
BDNF mimetic |
| NT-4 |
Recombinant protein |
Preclinical |
Natural ligand |
| AAV-BDNF |
Gene therapy |
Preclinical |
Viral vector delivery |
- Blood-brain barrier: Challenges in delivering TrkB-targeting compounds
- Peripheral effects: TrkB also expressed in non-CNS tissues
- Isoform specificity: Targeting full-length vs. truncated isoforms
- Roche: TrkB agonist program (discontinued)
- Neurocrine Biosciences: NTRK2-targeted compounds
- Academic groups: Gene therapy approaches
- Ntrk2⁻/⁻ mice: Die within first week of life
- Phenotype: Severe neuronal deficits, reduced brain size
- Insight: Essential for neuronal survival
- CNS-specific deletion: Viable, show learning deficits
- Adult-onset deletion: Reversible cognitive impairments
- TrkB overexpression: Enhanced synaptic plasticity
- Humanized models: For drug testing
- R684H: Associated with developmental disorders
- Y678C: Impaired kinase activity
- D668V: Reduced signaling capacity
- NTRK2 variants: Associated with:
- Alzheimer's disease risk
- Depression susceptibility
- Cognitive performance
| Partner |
Interaction Type |
Functional Outcome |
| SHC1 |
Phosphotyrosine binding |
MAPK pathway activation |
| PLCG1 |
Phosphotyrosine binding |
PLCγ pathway activation |
| PIK3R1 |
Direct binding |
PI3K/Akt pathway activation |
| NGFR (p75NTR) |
Co-receptor |
Enhanced signaling |
| BDNF |
Ligand binding |
Receptor activation |
| PTPN11 (SHP2) |
Dephosphorylation |
Negative regulation |
TrkB intersects with multiple signaling networks:
- Glutamate receptor signaling (NMDA, AMPA)
- Cytokine signaling pathways
- Metabolic pathways (mTOR, insulin signaling)
- Calcium signaling
¶ Detection and Analysis
- qPCR: mRNA expression quantification
- Western blot: Protein level analysis
- Immunohistochemistry: Tissue localization
- ELISA: Ligand binding studies
- Neuronal survival: MTT, caspase assays
- Synaptic plasticity: Electrophysiology (LTP/LTD)
- Axonal growth: Neurite outgrowth assays
The study of Trkb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Klein, R. et al. (1989). The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell. 66(2):395-403. PMID:2754250
- Barbacid, M. (1994). The Trk family of neurotrophin receptors. Journal of Neurobiology. 25(11):1386-1403. PMID:7848246
- Huang, E.J. & Reichardt, L.F. (2003). Trk receptors: roles in neuronal signal transduction. Annual Review of Biochemistry. 72:609-642. PMID:12676795
- Patapoutian, A. & Reichardt, L.F. (2001). Trk receptors: mediators of neurotrophin action. Current Opinion in Neurobiology. 11(3):272-280. PMID:11399424
- Chao, M.V. (2003). Neurotrophins and their receptors: a convergence point for many signaling pathways. Nature Reviews Neuroscience. 4(4):299-309. PMID:12671646
- Minichiello, L. (2009). TrkB signaling pathways in learning and memory. Learning & Memory. 16(10):553-562. PMID:19794191
- Lu, Y. et al. (2013). TrkB in hippocampal synaptic plasticity. Hippocampus. 23(9):849-858. PMID:23512883
- Autry, A.E. & Monteggia, L.M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews. 64(2):238-258. PMID:22407616
- Huang, E.J. & Reichardt, L.F. (2001). Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience. 24:677-736. PMID:11520916
- Kaplan, D.R. & Miller, F.D. (2000). Neurotrophin signal transduction in the nervous system. Current Opinion in Neurobiology. 10(3):381-391. PMID:10851172